Skip to content

Estrogen and Perimenopausal Depression

Dose Response Effects of Estrogen Augmentation in Mood & Memory in Perimenopausal Depression

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00229450
Enrollment
17
Registered
2005-09-29
Start date
2002-04-30
Completion date
2004-08-31
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Disorder, Major, Menopause

Keywords

depression, menopause, perimenopause, mood, memory, perimenopausal, antidepressant, estrogen

Brief summary

During perimenopause (the time just prior to menopause), women often notice many biological, psychological, and social changes. In particular, some women experience depressive symptoms during perimenopause that are severe enough to warrant antidepressant medication. Whether or not women with perimenopausal depression respond to antidepressant medication may depend on the level of estrogen in their blood. This study will investigate whether estrogen will help women who only partially respond to antidepressant medications, as well as examine how different doses of estrogen may affect individuals differently.

Interventions

DRUGEstrogen

0.625 mg/day of conjugated Estrogen

Sponsors

National Alliance for Research on Schizophrenia and Depression
CollaboratorOTHER
University of California, Los Angeles
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Clinical Diagnosis of Unipolar Major Depression, currently taking antidepressants * HAM-D between 10 and 17

Exclusion criteria

* History of Psychosis, breast cancer, smoking, dementia, clotting disorders * Current substance abuse

Design outcomes

Primary

MeasureTime frameDescription
Mood6 weeks17-item Hamilton Depression (HAM-D17) scores range from 0 to 50, and lower scores are better outcomes.

Secondary

MeasureTime frameDescription
Memory6 weeksThe Buschke Selective Reminding Task (SRT) is a standardized measure of verbal learning that presents 12 words to the subject who is asked to immediately recall as many words as possible. The examiner then presents words that the subject was unable to recall until the subject can recall all 12 words without prompting twice, or until the examiner has presented prompts up to 12 times. Consistent Long-Term Retrieval score is the number of words that the subject recalls without receiving prompts and indicates how well the subject consolidates the new information during the learning phase (encoding). Scores indicate the sum of consistent long-term word retrieval across the 12 trials and range from 0 to 144, with higher scores indicating better learning.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026